How Can We Help?
Pimodivir (VX-787, JNJ-63623872) is an antiviral drug which was developed as a treatment for influenza. It acts as an inhibitor of influenza virus polymerase basic protein 2, and has shown promising results in Phase II clinical trials.[1][2][3] However, in late 2021, Janssen announced that the clinical development of pimidivir had been halted due to lack of benefit over standard of care.[4]
See also
- Baloxavir marboxil
- Favipiravir
- Galidesivir
- Nitazoxanide
- Oseltamivir
- Peramivir
- Remdesivir
- Ribavirin
- Triazavirin
- Umifenovir
- Zanamivir
References
- ^ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, et al. (2018). "Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study". Antiviral Therapy. 23 (4): 335–344. doi:10.3851/IMP3212. PMID 29244026. S2CID 4005581.
- ^ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, et al. (March 2019). "Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial". The Journal of Infectious Diseases. 219 (7): 1026–1034. doi:10.1093/infdis/jiy547. PMID 30428049.
- ^ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC (July 2019). "Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference". Antiviral Research. 167: 45–67. doi:10.1016/j.antiviral.2019.04.006. PMC 7132446. PMID 30974127.
- ^ "Janssen's lead coronavirus vaccine shows preclinical promise". 4 September 2020.
Recent Comments